Genmab — Januar 2021
-
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer https://ir.genmab.com/news-releases/news-release-details/genmab-announces-phase-3-trial-tisotumab-vedotin-recurrent-or
-
Ja ATH er ATH som navnet siger. Det jeg i den forbindelse mente, var blot at slutkursen snarere er et målepunkt for beslutninger end ATH. Om det er sandheden ved jeg ikke, men syntes det er mere “fast” eller validt som målepunkt end ATH. Blot min måde at tegne og regne på
-
-
Genmab og Seattle Genetics arbejder på at søge om en accelereret godkendelse i USA baseret på fase-2 data. Midlet kan så eventuelt blive tilgængeligt for patienterne i andet halvår 2021.
-
-
Transactions with shares and linked securities in Genmab A/S m https://ml-eu.globenewswire.com/Resource/Download/d65dc065-2051-4cf7-99be-c97fbb4acd7b
ade by managerial employees and their closely associated persons -
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind